Used alongside other models, including the Lowe syndrome mouse (Bothwell et al., 2011; Festa et al., 2019), and patient-derived OCRL-deficient iPSC cells (Yan et al., 2021; Lo et al., 2024; Sharma et al., 2024) that can be cultured into brain or kidney organoids, it represents a valuable model going forwards. This evidence concerns the gene OCRL and oculocerebrorenal syndrome.